While we observed resistance to ceritinib in both fusions (Table 1; Figure 2C; Supplementary Figure S2), others have shown that ceritinib effectively overcomes G1269A in both ALK+ NSCLC [25, 47] and ALK+ ALCL [64] due to it stabilizing ALK's conformational dynamics and exhibiting increased potency for this mutant over WT ALK [48]. This evidence concerns the gene ALK and non-small cell lung carcinoma.